Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25

Well that's all folks, it's been a wild ride. PAR is basically washed up now, requiring two P3 clinical trials at 2 mg/kg dose. At least we know how much each will cost ~ 150 mill for both. PAR won't be able to raise these funds.

PAR's best options are to either sell up or to focus solely on the AUS market IMO. Unsure if they will even be able to deliver on any of their current promises. I doubt they will initiate stage 2 due to lack of funds. PAR blew it's chance when it gambled on the 1.5 mg/kg dose over 2 mg/kg dose. Also unsure why the burn rate is 8-11 million when all clinical trials have wrapped up.

Anyway they have a data package now that may be worth at least something to big pharma so PR should really start tapping big pharma before the SP reaches 1 cent.

My views, dyor, GLTAH